CN114778264A - Method for simultaneously accumulating, enriching and separating multiple arsenic forms in natural medicine on line based on micelle-solvent accumulation - Google Patents
Method for simultaneously accumulating, enriching and separating multiple arsenic forms in natural medicine on line based on micelle-solvent accumulation Download PDFInfo
- Publication number
- CN114778264A CN114778264A CN202210481619.3A CN202210481619A CN114778264A CN 114778264 A CN114778264 A CN 114778264A CN 202210481619 A CN202210481619 A CN 202210481619A CN 114778264 A CN114778264 A CN 114778264A
- Authority
- CN
- China
- Prior art keywords
- micelle
- stacking
- solvent
- enrichment
- natural medicine
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- RQNWIZPPADIBDY-UHFFFAOYSA-N arsenic atom Chemical group [As] RQNWIZPPADIBDY-UHFFFAOYSA-N 0.000 title claims abstract description 50
- 239000003814 drug Substances 0.000 title claims abstract description 26
- 238000000034 method Methods 0.000 title claims abstract description 25
- 239000002904 solvent Substances 0.000 title claims abstract description 21
- 238000009825 accumulation Methods 0.000 title claims abstract description 11
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 claims abstract description 78
- 239000000693 micelle Substances 0.000 claims abstract description 57
- 238000002347 injection Methods 0.000 claims abstract description 52
- 239000007924 injection Substances 0.000 claims abstract description 52
- 239000012491 analyte Substances 0.000 claims abstract description 37
- 238000001514 detection method Methods 0.000 claims abstract description 30
- 238000005251 capillar electrophoresis Methods 0.000 claims abstract description 23
- 229910021538 borax Inorganic materials 0.000 claims abstract description 22
- 239000004328 sodium tetraborate Substances 0.000 claims abstract description 22
- 235000010339 sodium tetraborate Nutrition 0.000 claims abstract description 22
- 239000000243 solution Substances 0.000 claims abstract description 20
- 229940079593 drug Drugs 0.000 claims abstract description 8
- 150000001450 anions Chemical class 0.000 claims abstract description 7
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 claims abstract description 6
- 239000005350 fused silica glass Substances 0.000 claims abstract description 6
- GACDQMDRPRGCTN-KQYNXXCUSA-N 3'-phospho-5'-adenylyl sulfate Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](COP(O)(=O)OS(O)(=O)=O)[C@@H](OP(O)(O)=O)[C@H]1O GACDQMDRPRGCTN-KQYNXXCUSA-N 0.000 claims abstract 2
- 238000000926 separation method Methods 0.000 claims description 33
- 239000000523 sample Substances 0.000 claims description 26
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 claims description 21
- 239000000872 buffer Substances 0.000 claims description 21
- 239000012488 sample solution Substances 0.000 claims description 14
- 239000003960 organic solvent Substances 0.000 claims description 12
- 241000512259 Ascophyllum nodosum Species 0.000 claims description 9
- KCXFHTAICRTXLI-UHFFFAOYSA-N propane-1-sulfonic acid Chemical compound CCCS(O)(=O)=O KCXFHTAICRTXLI-UHFFFAOYSA-N 0.000 claims description 8
- 239000006228 supernatant Substances 0.000 claims description 6
- SGRHVVLXEBNBDV-UHFFFAOYSA-N 1,6-dibromohexane Chemical compound BrCCCCCCBr SGRHVVLXEBNBDV-UHFFFAOYSA-N 0.000 claims description 5
- 239000007864 aqueous solution Substances 0.000 claims description 5
- 239000000203 mixture Substances 0.000 claims description 5
- -1 sodium dimethylarsine Chemical compound 0.000 claims description 4
- 238000002360 preparation method Methods 0.000 claims description 3
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 claims 1
- IDDBICIFODFKQO-UHFFFAOYSA-N methylarsane Chemical compound [AsH2]C IDDBICIFODFKQO-UHFFFAOYSA-N 0.000 claims 1
- 229910052708 sodium Inorganic materials 0.000 claims 1
- 239000011734 sodium Substances 0.000 claims 1
- 229910052785 arsenic Inorganic materials 0.000 abstract description 31
- 238000005370 electroosmosis Methods 0.000 abstract description 16
- 230000035945 sensitivity Effects 0.000 abstract description 10
- 238000005515 capillary zone electrophoresis Methods 0.000 abstract description 8
- 239000002888 zwitterionic surfactant Substances 0.000 abstract description 7
- 239000011248 coating agent Substances 0.000 abstract description 5
- 238000000576 coating method Methods 0.000 abstract description 5
- 239000007853 buffer solution Substances 0.000 abstract 1
- 230000000694 effects Effects 0.000 description 16
- 241000894007 species Species 0.000 description 14
- OGGXGZAMXPVRFZ-UHFFFAOYSA-N dimethylarsinic acid Chemical compound C[As](C)(O)=O OGGXGZAMXPVRFZ-UHFFFAOYSA-N 0.000 description 13
- 238000013508 migration Methods 0.000 description 13
- 230000005012 migration Effects 0.000 description 13
- 238000004458 analytical method Methods 0.000 description 8
- 230000001965 increasing effect Effects 0.000 description 7
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 6
- LZZYPRNAOMGNLH-UHFFFAOYSA-M Cetrimonium bromide Chemical compound [Br-].CCCCCCCCCCCCCCCC[N+](C)(C)C LZZYPRNAOMGNLH-UHFFFAOYSA-M 0.000 description 5
- 150000001875 compounds Chemical class 0.000 description 5
- 238000001962 electrophoresis Methods 0.000 description 5
- 150000001495 arsenic compounds Chemical class 0.000 description 4
- 230000015572 biosynthetic process Effects 0.000 description 4
- 230000003247 decreasing effect Effects 0.000 description 4
- 229940093920 gynecological arsenic compound Drugs 0.000 description 4
- UKHVLWKBNNSRRR-UHFFFAOYSA-M quaternium-15 Chemical compound [Cl-].C1N(C2)CN3CN2C[N+]1(CC=CCl)C3 UKHVLWKBNNSRRR-UHFFFAOYSA-M 0.000 description 4
- 230000002441 reversible effect Effects 0.000 description 4
- 239000012086 standard solution Substances 0.000 description 4
- 230000007423 decrease Effects 0.000 description 3
- 238000001095 inductively coupled plasma mass spectrometry Methods 0.000 description 3
- 230000002035 prolonged effect Effects 0.000 description 3
- 238000011160 research Methods 0.000 description 3
- 239000004094 surface-active agent Substances 0.000 description 3
- CPELXLSAUQHCOX-UHFFFAOYSA-M Bromide Chemical compound [Br-] CPELXLSAUQHCOX-UHFFFAOYSA-M 0.000 description 2
- 125000000129 anionic group Chemical group 0.000 description 2
- AQLMHYSWFMLWBS-UHFFFAOYSA-N arsenite(1-) Chemical compound O[As](O)[O-] AQLMHYSWFMLWBS-UHFFFAOYSA-N 0.000 description 2
- 239000003093 cationic surfactant Substances 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 238000010586 diagram Methods 0.000 description 2
- 239000003651 drinking water Substances 0.000 description 2
- 235000020188 drinking water Nutrition 0.000 description 2
- 239000003792 electrolyte Substances 0.000 description 2
- 238000001287 electrothermal atomic absorption spectrometry Methods 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 235000013305 food Nutrition 0.000 description 2
- 238000001676 hydride generation atomic fluorescence spectroscopy Methods 0.000 description 2
- 230000007246 mechanism Effects 0.000 description 2
- 238000004094 preconcentration Methods 0.000 description 2
- 238000011084 recovery Methods 0.000 description 2
- 239000012146 running buffer Substances 0.000 description 2
- 231100000331 toxic Toxicity 0.000 description 2
- 230000002588 toxic effect Effects 0.000 description 2
- 231100000419 toxicity Toxicity 0.000 description 2
- 230000001988 toxicity Effects 0.000 description 2
- 230000001052 transient effect Effects 0.000 description 2
- DJHGAFSJWGLOIV-UHFFFAOYSA-K Arsenate3- Chemical compound [O-][As]([O-])([O-])=O DJHGAFSJWGLOIV-UHFFFAOYSA-K 0.000 description 1
- 208000008316 Arsenic Poisoning Diseases 0.000 description 1
- 206010005003 Bladder cancer Diseases 0.000 description 1
- 208000024172 Cardiovascular disease Diseases 0.000 description 1
- 229920000858 Cyclodextrin Polymers 0.000 description 1
- 206010058467 Lung neoplasm malignant Diseases 0.000 description 1
- 208000012902 Nervous system disease Diseases 0.000 description 1
- 208000025966 Neurological disease Diseases 0.000 description 1
- 208000000453 Skin Neoplasms Diseases 0.000 description 1
- 208000007097 Urinary Bladder Neoplasms Diseases 0.000 description 1
- 241000607479 Yersinia pestis Species 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 239000002280 amphoteric surfactant Substances 0.000 description 1
- 229940000489 arsenate Drugs 0.000 description 1
- ORLOBEXOFQEWFQ-UHFFFAOYSA-N arsenocholine Chemical compound C[As+](C)(C)CCO ORLOBEXOFQEWFQ-UHFFFAOYSA-N 0.000 description 1
- 238000001636 atomic emission spectroscopy Methods 0.000 description 1
- 229950004243 cacodylic acid Drugs 0.000 description 1
- 238000011088 calibration curve Methods 0.000 description 1
- 230000000711 cancerogenic effect Effects 0.000 description 1
- 238000000906 capillary electrophoresis-inductively coupled plasma mass spectrometry Methods 0.000 description 1
- 231100000315 carcinogenic Toxicity 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- 230000035622 drinking Effects 0.000 description 1
- 230000000482 effect on migration Effects 0.000 description 1
- 230000005684 electric field Effects 0.000 description 1
- 230000005520 electrodynamics Effects 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 239000000284 extract Substances 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 238000000589 high-performance liquid chromatography-mass spectrometry Methods 0.000 description 1
- VDEGQTCMQUFPFH-UHFFFAOYSA-N hydroxy-dimethyl-arsine Natural products C[As](C)O VDEGQTCMQUFPFH-UHFFFAOYSA-N 0.000 description 1
- 238000002513 implantation Methods 0.000 description 1
- 238000011065 in-situ storage Methods 0.000 description 1
- 238000009616 inductively coupled plasma Methods 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 238000002218 isotachophoresis Methods 0.000 description 1
- 238000012417 linear regression Methods 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 201000005202 lung cancer Diseases 0.000 description 1
- 208000020816 lung neoplasm Diseases 0.000 description 1
- 230000014759 maintenance of location Effects 0.000 description 1
- 239000011159 matrix material Substances 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- QYPPRTNMGCREIM-UHFFFAOYSA-N methylarsonic acid Chemical compound C[As](O)(O)=O QYPPRTNMGCREIM-UHFFFAOYSA-N 0.000 description 1
- 150000002892 organic cations Chemical class 0.000 description 1
- 230000008520 organization Effects 0.000 description 1
- 238000012856 packing Methods 0.000 description 1
- 239000012466 permeate Substances 0.000 description 1
- 239000000575 pesticide Substances 0.000 description 1
- 230000003234 polygenic effect Effects 0.000 description 1
- 244000144977 poultry Species 0.000 description 1
- 230000005180 public health Effects 0.000 description 1
- 238000011002 quantification Methods 0.000 description 1
- 125000001453 quaternary ammonium group Chemical group 0.000 description 1
- 238000005070 sampling Methods 0.000 description 1
- 235000014102 seafood Nutrition 0.000 description 1
- 201000000849 skin cancer Diseases 0.000 description 1
- IHQKEDIOMGYHEB-UHFFFAOYSA-M sodium dimethylarsinate Chemical compound [Na+].C[As](C)([O-])=O IHQKEDIOMGYHEB-UHFFFAOYSA-M 0.000 description 1
- 238000001179 sorption measurement Methods 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 230000002195 synergetic effect Effects 0.000 description 1
- 238000001269 time-of-flight mass spectrometry Methods 0.000 description 1
- 201000005112 urinary bladder cancer Diseases 0.000 description 1
Images
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N1/00—Sampling; Preparing specimens for investigation
- G01N1/28—Preparing specimens for investigation including physical details of (bio-)chemical methods covered elsewhere, e.g. G01N33/50, C12Q
- G01N1/40—Concentrating samples
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N1/00—Sampling; Preparing specimens for investigation
- G01N1/28—Preparing specimens for investigation including physical details of (bio-)chemical methods covered elsewhere, e.g. G01N33/50, C12Q
- G01N1/34—Purifying; Cleaning
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N1/00—Sampling; Preparing specimens for investigation
- G01N1/28—Preparing specimens for investigation including physical details of (bio-)chemical methods covered elsewhere, e.g. G01N33/50, C12Q
- G01N1/40—Concentrating samples
- G01N2001/4038—Concentrating samples electric methods, e.g. electromigration, electrophoresis, ionisation
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Physics & Mathematics (AREA)
- Chemical & Material Sciences (AREA)
- Analytical Chemistry (AREA)
- Biochemistry (AREA)
- General Physics & Mathematics (AREA)
- Immunology (AREA)
- Pathology (AREA)
- Biomedical Technology (AREA)
- Molecular Biology (AREA)
- Engineering & Computer Science (AREA)
- Other Investigation Or Analysis Of Materials By Electrical Means (AREA)
Abstract
Description
技术领域technical field
本发明属于天然药物中砷形态的分离富集领域,涉及一种用毛细管电泳技术在线富集砷的方法,具体地说是一种基于胶束-溶剂堆积对天然药物中多种砷形态同时在线堆积富集、分离方法。The invention belongs to the field of separation and enrichment of arsenic forms in natural medicines, and relates to a method for on-line enrichment of arsenic by capillary electrophoresis technology, in particular to a simultaneous online-on-line method for multiple arsenic forms in natural medicines based on micelle-solvent accumulation Stacking enrichment and separation methods.
背景技术Background technique
砷(As)是地壳中的一种天然元素,含有50多种具有不同毒性的化合物,广泛分布于大气、水和土地。由于工业污染渗透到生活的方方面面,人们暴露于高浓度的无机砷,这是最有毒的物种。导致心血管疾病、神经系统疾病、糖尿病或皮肤膀胱癌和肺癌的慢性砷中毒可由长期接触无机砷引起,主要通过饮用受污染的水、食用用此类水加工的食品以及用富砷水灌溉的食品。由于砷对人体的严重影响,被世界卫生组织(WHO)列为引起重大公共卫生问题的10种化学品之一。世卫组织关于饮用水中砷的最新指数为0.01mg/L,当剂量超过6×10-4mg/L时,存在致癌风险。然而,由于测量困难以及从饮用水中去除砷的实际困难,该指数值的制定只是暂时的。尽管砷对人类的危害极大,但它被用作某些杀虫剂和家禽饲料配方中的一种成分,以防止害虫和促进生长。因此,对砷含量的准确检测技术进行了不断的研究,这是一项极其重要而深远的研究课题。Arsenic (As) is a natural element in the earth's crust that contains more than 50 compounds of varying toxicity and is widely distributed in the atmosphere, water and land. As industrial pollution permeates every aspect of life, people are exposed to high concentrations of inorganic arsenic, the most toxic species. Chronic arsenic poisoning leading to cardiovascular disease, neurological disease, diabetes or skin, bladder and lung cancer can be caused by prolonged exposure to inorganic arsenic, mainly through drinking contaminated water, eating foods processed from this water, and irrigating with arsenic-rich water. food. Due to the serious effects of arsenic on the human body, it is listed by the World Health Organization (WHO) as one of the 10 chemicals that cause major public health problems. The latest WHO index on arsenic in drinking water is 0.01mg/L, and when the dose exceeds 6×10 -4 mg/L, there is a carcinogenic risk. However, due to measurement difficulties and practical difficulties in removing arsenic from drinking water, the development of this index value is only tentative. Although arsenic is extremely harmful to humans, it is used as an ingredient in certain pesticides and in poultry feed formulations to prevent pests and promote growth. Therefore, the accurate detection technology of arsenic content has been continuously studied, which is an extremely important and far-reaching research topic.
砷以无机形式(亚砷酸盐和砷酸盐)和有机形式(亚砷酸盐、砷胆碱、一甲基胂酸和二甲基胂酸)存在,不同种类的砷具有不同的毒性,其中无机砷化合物比有机砷化合物(如海产品中的砷化合物)更具毒性。迄今为止,电感耦合等离子体质谱法(ICP-MS)和氢化物发生原子荧光光谱法(HG-AFS)是分离和分析砷物种最常用的组合技术。此外,还开发了其他重要的分析方法来检测实际样品中的痕量砷,如高效液相色谱法和电感耦合等离子体质谱法(HPLC-ICP-MS),ICP光学发射光谱法(ICP-OES),和四极飞行时间质谱(ESI-qTOF-MS)。毛细管电泳(CE)具有很强的分离性能,但毛细管的短光程和小的进样量降低了其灵敏度。为了克服这些限制,CE中的各种在线样品预富集技术是富集砷物种的有效方法,包括现场强化样品注入(FESI)和瞬态等速电泳(t-ITP)。此外,许多与CE结合的技术,如CE与氢化物发生电热原子吸收光谱法(CE-HG-ETAAS)、CE-ICP-MS和CE与电喷雾质谱联用(CE-ESI-MS),也是解决这些限制的理想方法。然而,毛细管电泳直接检测砷具有高效、简便的优点,具有巨大的吸引力。因此,应用一种新的高灵敏度预富集方法检测砷仍然是一个有趣的研究课题。Arsenic exists in inorganic forms (arsenite and arsenate) and organic forms (arsenite, arsenocholine, monomethylarsinic acid and dimethylarsinic acid), and different species of arsenic have different toxicity, Among them, inorganic arsenic compounds are more toxic than organic arsenic compounds (such as arsenic compounds in seafood). To date, inductively coupled plasma mass spectrometry (ICP-MS) and hydride generation atomic fluorescence spectrometry (HG-AFS) are the most commonly used combined techniques for the separation and analysis of arsenic species. In addition, other important analytical methods have been developed to detect trace amounts of arsenic in real samples, such as high performance liquid chromatography and inductively coupled plasma mass spectrometry (HPLC-ICP-MS), ICP optical emission spectrometry (ICP-OES) ), and quadrupole time-of-flight mass spectrometry (ESI-qTOF-MS). Capillary electrophoresis (CE) has strong separation performance, but the short path length and small injection volume of capillary tubes reduce its sensitivity. To overcome these limitations, various in-line sample preconcentration techniques in CE are effective methods to enrich arsenic species, including enhanced in situ sample injection (FESI) and transient isotachophoresis (t-ITP). In addition, many techniques combined with CE, such as CE-Hydride Electrothermal Atomic Absorption Spectrometry (CE-HG-ETAAS), CE-ICP-MS, and CE-ESI-MS (CE-ESI-MS), are also Ideal way to get around these limitations. However, the direct detection of arsenic by capillary electrophoresis is highly attractive due to its high efficiency and simplicity. Therefore, the application of a new high-sensitivity pre-enrichment method for the detection of arsenic remains an interesting research topic.
CE在线预浓缩的典型方法有FESI、t-ITP和动态pH连接。除上述富集技术外,胶束-溶剂堆积(MSS)是近年来新兴的在线样品浓缩技术之一。此外,瞬态捕获、通过胶束崩塌(AFMC)聚焦分析物以及胶束-环糊精堆叠(MCDS)对于类似地提高检测灵敏度是有利的。MSS最早由Joselito P.Quirino于2009年提出,通过在样品溶液中使用胶束和背景溶液(BGS)中使用有机溶剂逆转有机阳离子的有效电泳迁移方向来实现。聚焦效应是通过在胶束和有机溶剂修饰的BGS之间的边界区,目标分析物的有效电泳迁移率的反转来实现的。MSS优越的检测灵敏度引起了广泛关注,并在此基础上不断创新。创新主要集中在胶束的类型以及有机溶剂和胶束的位置。一般来说,以前的大多数研究都集中在使用阳离子表面活性剂检测和分离MSS中的阴离子分析物。MSS中通常有三种模型:BGS中有机溶剂和胶束中混合样品的一步堆叠,BGS中有机溶剂和样品及胶束注入的两步堆叠,以及有机溶剂、分析物和胶束注入的三步堆叠,分别用于检测各种化合物。在电动喷射和流体动力喷射之间选择喷射模型也可以显著提高性能,特别是在实现最低检测限方面。根据上述说法,开发一种更灵敏、更有效的MSS技术是值得探索的。Typical methods for in-line preconcentration of CE are FESI, t-ITP and dynamic pH ligation. In addition to the above enrichment techniques, micelle-solvent stacking (MSS) is one of the emerging online sample enrichment techniques in recent years. Furthermore, transient capture, focusing of analytes by micelle collapse (AFMC), and micelle-cyclodextrin stacking (MCDS) are advantageous for similarly enhancing detection sensitivity. MSS, first proposed by Joselito P. Quirino in 2009, is achieved by reversing the effective electrophoretic migration direction of organic cations using micelles in the sample solution and organic solvents in the background solution (BGS). The focusing effect is achieved by the inversion of the effective electrophoretic mobility of the target analyte in the boundary region between the micelles and the organic solvent-modified BGS. The superior detection sensitivity of MSS has aroused widespread attention and continues to innovate on this basis. Innovations have focused on the type of micelles and the location of organic solvents and micelles. In general, most previous studies have focused on the detection and separation of anionic analytes in MSS using cationic surfactants. There are generally three models in MSS: one-step stacking of organic solvent in BGS and mixed sample in micelles, two-step stacking of organic solvent and sample and micelle injection in BGS, and three-step stacking of organic solvent, analyte and micelle injection , respectively, for the detection of various compounds. Choosing an injection model between electric and hydrodynamic injection can also significantly improve performance, especially in achieving the lowest detection limits. According to the above, the development of a more sensitive and efficient MSS technique is worth exploring.
本发明建立了一种新的两步叠加模型,用于检测涂层毛细管区带电泳(CZE)中的四种砷。用海美溴铵(HDMB)对毛细管壁进行涂层,这是反转电渗流的重要步骤。两性离子表面活性剂3-(N,N-二甲基棕榈氨基)丙烷磺酸盐(PAPS)作为胶束和目标分析物混合后作为样品溶液通过负电压电动注入引入,然后再单独注入有机溶液,促进形成MSS边界,以实现样品堆积的关键步骤。研究了多种优化条件,包括胶束类型和浓度、甲醇百分比、硼砂缓冲液浓度和进样时间,以提高堆积效率和分辨率。该方法用于海带中砷的测定。The present invention establishes a new two-step superposition model for detecting four kinds of arsenic in coated capillary zone electrophoresis (CZE). Coating of capillary walls with hexamethylene bromide (HDMB) is an important step in reversing electroosmotic flow. The zwitterionic surfactant 3-(N,N-dimethylpalmitamido)propanesulfonate (PAPS) was mixed as micelles with the target analyte and introduced as a sample solution by electrokinetic injection at a negative voltage, and then injected into the organic solution separately , which facilitates the formation of MSS boundaries to achieve a critical step in sample stacking. Various optimized conditions were investigated, including micelle type and concentration, methanol percentage, borax buffer concentration, and injection time to improve stacking efficiency and resolution. This method was used for the determination of arsenic in kelp.
发明内容SUMMARY OF THE INVENTION
本发明的目的针对现有技术的不足,提供一种基于胶束-溶剂堆积对天然药物中多种砷形态同时在线堆积富集、分离方法,比以往富集方法更加快速高效灵敏,适用于具有复杂基质的天然药物中砷的检测。The object of the present invention is to provide a method for simultaneous online accumulation and separation of various arsenic forms in natural medicine based on micelle-solvent accumulation, which is more rapid, efficient and sensitive than previous enrichment methods, and is suitable for those with Detection of arsenic in natural medicines in complex matrices.
本发明方法采用以下技术方案实现:The inventive method adopts the following technical solutions to realize:
步骤(1)、目标分析物样品制备:Step (1), target analyte sample preparation:
将天然药物洗净干燥、粉碎后过筛与HNO3混合后40-45℃下超声0.5-1h,再置于室温下振摇1.5-2h,最后高速离心10-15min,取出上清液。将上清液用NaOH调至中和,得到目标分析物样品;Wash, dry, pulverize, sieve and mix with HNO 3 , ultrasonicate for 0.5-1h at 40-45°C, shake at room temperature for 1.5-2h, and finally centrifuge at high speed for 10-15min, and remove the supernatant. The supernatant was neutralized with NaOH to obtain the target analyte sample;
作为优选,所述天然药物指代海带;Preferably, the natural medicine refers to kelp;
作为优选,天然药物与HNO3的质量体积比为200mg:5mL;Preferably, the mass-volume ratio of natural medicine and HNO 3 is 200mg: 5mL;
作为优选,HNO3的浓度为2%(w/v,mg/mL);Preferably, the concentration of HNO 3 is 2% (w/v, mg/mL);
作为优选,离心的转速为4000-5000r/min;Preferably, the centrifugal speed is 4000-5000r/min;
步骤(2)、目标分析物样品富集、分离:Step (2), target analyte sample enrichment and separation:
2-1、活化毛细管柱2-1. Activated capillary column
采用1%(w/v,g/mL)海美溴铵(HDMB)涂层熔融石英毛细管20-25分钟,以满足阴离子和毛细管之间相同EOF方向的条件。A 1% (w/v, g/mL) hexamethylene bromide (HDMB)-coated fused silica capillary was used for 20-25 min to satisfy the condition of the same EOF orientation between the anion and the capillary.
2-2、对活化毛细管柱进样前进行硼砂缓冲液冲洗5-10分钟。2-2. Rinse the activated capillary column with borax buffer for 5-10 minutes before injection.
作为优选,所述硼砂缓冲液浓度为25-100mM,优选为100mM。Preferably, the concentration of the borax buffer is 25-100 mM, preferably 100 mM.
作为优选,所述硼砂缓冲液pH为8.8-9.4,更为优选为9.2。Preferably, the pH of the borax buffer is 8.8-9.4, more preferably 9.2.
2-3、毛细管柱中,胶束和目标分析物混合后作为样品溶液在负压下注入堆叠30-240s,然后负压下注射作为有机溶剂的甲醇水溶液,被扫描的分析物由胶束带到MSS边界,以实现样品堆积、分离;其中所述胶束采用3-(N,N-二甲基棕榈氨基)丙烷磺酸盐PAPS。2-3. In the capillary column, the micelles and the target analyte are mixed and injected into the stack as a sample solution under negative pressure for 30-240s, and then an aqueous methanol solution as an organic solvent is injected under negative pressure. The scanned analyte is bound by the micelles. to the MSS boundary to achieve sample stacking and separation; wherein the micelles use 3-(N,N-dimethylpalmitamido)propane sulfonate PAPS.
作为优选,毛细管电泳条件:检测波长为192nm,分离负压为-20kV,温度为20℃。Preferably, the capillary electrophoresis conditions: the detection wavelength is 192nm, the separation negative pressure is -20kV, and the temperature is 20°C.
作为优选,所述胶束浓度为10-40mM,更为优选为20mM。Preferably, the micelle concentration is 10-40 mM, more preferably 20 mM.
作为优选,所述胶束的注入时间为180s。Preferably, the injection time of the micelle is 180s.
作为优选,所述胶束的注入负压为-10kV。Preferably, the injection negative pressure of the micelle is -10kV.
作为优选,所述甲醇水溶液的进样参数为注射动力-10kV、注射压力50mbar、注射时间5s。Preferably, the injection parameters of the methanol aqueous solution are injection power-10kV, injection pressure 50mbar, and injection time 5s.
作为优选,所述甲醇水溶液体积含量为40-100%(v/v),优选为60%(v/v)。Preferably, the volume content of the methanol aqueous solution is 40-100% (v/v), preferably 60% (v/v).
上述多种砷形态的富集因子分别为[As(Ⅴ)、As(Ⅲ)、MMA和DMA]1230、840、3820和1450。检测限(S/N=3)范围为0.382至0.911ng/mL。毛细管内重复性(%RSD,N=3)迁移时间为0.5-1.0%,峰面积为0.3-0.9%。The enrichment factors of the above-mentioned various forms of arsenic are [As(V), As(III), MMA and DMA] 1230, 840, 3820 and 1450, respectively. The detection limit (S/N=3) ranged from 0.382 to 0.911 ng/mL. Intracapillary repeatability (% RSD, N=3) migration time was 0.5-1.0% and peak area was 0.3-0.9%.
本发明的优点在于:The advantages of the present invention are:
(1)本发明提出涂层CE中的电动进样辅助MSS。(1) The present invention proposes an electrodynamic sampling assisted MSS in the coated CE.
(2)本发明提出两性离子表面活性剂3-(N,N-二甲基棕榈氨基)丙烷磺酸盐PAPS作为MSS中的胶束溶液,然后用海美溴铵HDMB逆转EOF。(2) The present invention proposes the zwitterionic surfactant 3-(N,N-dimethylpalmitamido)propane sulfonate PAPS as a micellar solution in MSS, and then reverses EOF with trimetium bromide HDMB.
(3)本发明提出与CZE中典型注射液相比,As(V)、As(Ⅲ)、MMA和DMA的富集因子分别为1230、840、3820和1450。(3) Compared with the typical injection in CZE, the present invention proposes that the enrichment factors of As(V), As(III), MMA and DMA are 1230, 840, 3820 and 1450, respectively.
(4)本发明利用涂层毛细管电泳从胶束到溶剂堆积法检测天然药物中的砷,该方法不仅实现了砷形态的快速检测,也极大地提高了毛细管电泳样品在线富集的灵敏度。与传统的砷检测方法相比,该方法实现了典型砷形态的高效检测和分离。(4) The present invention utilizes coating capillary electrophoresis to detect arsenic in natural medicines from micelles to solvent accumulation. This method not only realizes the rapid detection of arsenic forms, but also greatly improves the sensitivity of capillary electrophoresis sample online enrichment. Compared with traditional arsenic detection methods, this method achieves efficient detection and separation of typical arsenic species.
附图说明Description of drawings
图1是本发明的富集机理图。Figure 1 is a diagram of the enrichment mechanism of the present invention.
图2是胶束种类的影响(PAPS、CTAB、CTAC);其中CE条件:样品溶液中胶束浓度为10mM,分析物浓度为10mg/L,-10kV下注射60s;MeOH(100%)在50mbar下注射5s;背景溶液:100mM硼砂缓冲液。Figure 2 is the effect of micelle species (PAPS, CTAB, CTAC); CE conditions: micelle concentration in the sample solution is 10mM, analyte concentration is 10mg/L, injection at -10kV for 60s; MeOH (100%) at 50mbar down injection for 5 s; background solution: 100 mM borax buffer.
图3是PAPS浓度的影响(0,5,10,20,30,40mM);其他CE条件与图2相同。Figure 3 is the effect of PAPS concentration (0, 5, 10, 20, 30, 40 mM); other CE conditions are the same as in Figure 2.
图4是甲醇含量的影响(40%,60%,80%,100%);CE条件:与图2相同。Figure 4 is the effect of methanol content (40%, 60%, 80%, 100%); CE conditions: same as Figure 2.
图5是硼砂浓度的影响(25,50,75,100mM);A:电泳图,1-As(Ⅴ),2-MMA,3-DMA,4-As(Ⅲ);(B)表观迁移率,CE条件:样品溶液中PAPS浓度为20mM,分析物浓度为10mg/L,-10kV下注射60s;MeOH(60%)在50mbar下注射5s;背景溶液:100mM硼砂缓冲液。Figure 5 is the effect of borax concentration (25, 50, 75, 100 mM); A: electropherogram, 1-As(V), 2-MMA, 3-DMA, 4-As(III); (B) apparent mobility , CE conditions: PAPS concentration in sample solution is 20mM, analyte concentration is 10mg/L, injection at -10kV for 60s; MeOH (60%) injection at 50mbar for 5s; background solution: 100mM borax buffer.
图6是缓冲液pH的影响(8.8,9.0,9.2,9.4);其他条件与图5相同。Figure 6 is the effect of buffer pH (8.8, 9.0, 9.2, 9.4); other conditions are the same as in Figure 5.
图7是样品注射时间的影响(30,60,120,180,240s);分析物浓度为1mg/L,其他条件与图6相同。Figure 7 is the effect of sample injection time (30, 60, 120, 180, 240s); the analyte concentration is 1 mg/L, and other conditions are the same as in Figure 6.
图8A是最优条件下分析海带的加标电泳图60s(a)和5s(b)。Figure 8A is a spiked electropherogram 60s (a) and 5s (b) of the analysis of kelp under optimal conditions.
图8B是通过两步法叠加和典型注射标准溶液的电泳图;两步堆叠:将含有1mg/L分析物混标和20mM PAPS的样品溶液在-10kV下注入180s。甲醇(60%)50mbar注射5s,典型注射:无胶束的目标分析物50mbar注射3s,混合砷浓度为10.0mg/L。Figure 8B is an electropherogram overlaid by a two-step method and a typical injection of a standard solution; two-step stack: a sample solution containing 1 mg/L analyte mix and 20 mM PAPS was injected at -10 kV for 180 s. Methanol (60%) was injected at 50 mbar for 5 s, typical injection: target analyte without micelles was injected at 50 mbar for 3 s, and the mixed arsenic concentration was 10.0 mg/L.
具体实施方式Detailed ways
如前所述,鉴于现有技术的不足,本案发明人经长期研究和大量实践,提出了本发明的技术方案,其主要是依据至少包括:1)本发明利用两性离子表面活性剂3-(N,N-二甲基棕榈氨基)丙烷磺酸盐(PAPS)在共电渗流(co-EOF)中通过电动注射和胶束到溶剂堆积(MSS)对四种砷物种[As(Ⅴ)、As(Ⅲ)、一甲基胂酸钠(MMA)和二甲基胂酸钠(DMA)]进行有效和灵敏的两步堆积毛细管区带电泳(CZE)。(2)用海美溴铵(HDMB)对毛细管壁进行涂层,逆转EOF,以满足阴离子和毛细管之间相同EOF方向的条件。(3)本发明将两性离子表面活性剂3-(N,N-二甲基棕榈氨基)丙烷磺酸盐(PAPS)作为胶束和目标分析物混合后作为样品溶液通过负电压电动注入引入,然后再单独注入有机溶液,形成MSS边界以实现样品堆积。当施加负分离电压时,在强反向EOF作用下,所有化合物都向阳极迁移。有机溶剂的存在使滞留因子(κ)降低。当κ降低到分析物有效电泳迁移率[μep(a′)]发生反转并直接转到阳极时,阴离子分析物的有效电泳迁移率[μep *(a′)]可由公式(1)得到:As mentioned above, in view of the deficiencies of the prior art, the inventor of the present invention, through long-term research and a large number of practices, has proposed the technical solution of the present invention, which is mainly based on at least including: 1) the present invention utilizes a zwitterionic surfactant 3-( N,N-Dimethylpalmitamino)propanesulfonate (PAPS) in co-electroosmotic flow (co-EOF) via electrokinetic injection and micelle-to-solvent stacking (MSS) on four arsenic species [As(V), As(III), sodium monomethylarsinate (MMA) and sodium dimethylarsinate (DMA)] for efficient and sensitive two-step stacking capillary zone electrophoresis (CZE). (2) Coating the capillary wall with hexamethylene bromide (HDMB) reverses the EOF to satisfy the condition of the same EOF direction between the anion and the capillary. (3) In the present invention, the zwitterionic surfactant 3-(N,N-dimethylpalmitoamino)propane sulfonate (PAPS) is mixed with the target analyte as a micelle and introduced as a sample solution by electrokinetic injection at a negative voltage, The organic solution is then injected separately to form MSS boundaries for sample stacking. When a negative separation voltage is applied, all compounds migrate towards the anode under strong reverse EOF. The presence of organic solvents reduces the retention factor (κ). When κ is lowered to the point where the effective electrophoretic mobility of the analyte [μ ep (a′)] is reversed and directly transferred to the anode, the effective electrophoretic mobility of the anionic analyte [μ ep * (a′)] can be obtained from equation (1) get:
式中,μep(a′)为被分析物的电泳迁移率,μep(mc)为胶束的电泳迁移率。当胶束崩塌导致μep *(a′)的κ为0时,μep(a′)指向阴极,被分析物在MSSB处积累。由此,公式(1)可被简化为:In the formula, μ ep (a′) is the electrophoretic mobility of the analyte, and μ ep (mc) is the electrophoretic mobility of the micelle. When the κ of μep * (a′) is 0 due to the collapse of the micelles, μep (a′) points to the cathode and the analyte accumulates at the MSSB. Thus, formula (1) can be simplified to:
最后,在连续电场作用下,所有表面活性剂都穿过MSSB,堆叠的分析物通过CZE进行分离。由于四个As物种在电泳中具有不同的迁移速率,因此它们依次通过紫外检测器被检测分析。Finally, under the continuous electric field, all surfactants pass through the MSSB and the stacked analytes are separated by CZE. Since the four As species have different migration rates in electrophoresis, they are sequentially detected and analyzed by a UV detector.
为了使本发明的目的、技术方案及优点更加清楚明白,以下结合附图及实施例,对本发明进行进一步详细说明。应当理解,此处所描述的具体实施例仅仅用以解释本发明,并不用于限定本发明。此外,下面所描述的本发明各个实施方式中所涉及到的技术特征只要彼此之间未构成冲突就可以相互组合。In order to make the objectives, technical solutions and advantages of the present invention clearer, the present invention will be further described in detail below with reference to the accompanying drawings and embodiments. It should be understood that the specific embodiments described herein are only used to explain the present invention, but not to limit the present invention. In addition, the technical features involved in the various embodiments of the present invention described below can be combined with each other as long as they do not conflict with each other.
图1是本发明的富集机理图,一种基于胶束-溶剂堆积对天然药物中多种砷形态同时在线堆积富集、分离方法,包括如下步骤:Fig. 1 is the enrichment mechanism diagram of the present invention, a kind of on-line accumulation enrichment and separation method for multiple arsenic forms in natural medicines based on micelle-solvent accumulation, comprising the following steps:
步骤(1)、目标分析物样品制备:Step (1), target analyte sample preparation:
将天然药物洗净干燥、粉碎后过筛与HNO3混合后40-45℃下超声0.5-1h,再置于室温下振摇1.5-2h,最后高速离心10-15min,取出上清液。将上清液用NaOH调至中和,得到目标分析物样品;Wash, dry, pulverize, sieve and mix with HNO 3 , ultrasonicate for 0.5-1h at 40-45°C, shake at room temperature for 1.5-2h, and finally centrifuge at high speed for 10-15min, and remove the supernatant. The supernatant was neutralized with NaOH to obtain the target analyte sample;
作为优选,所述天然药物指代海带;Preferably, the natural medicine refers to kelp;
作为优选,天然药物与HNO3的质量体积比为200mg:5mL;Preferably, the mass-volume ratio of natural medicine and HNO 3 is 200mg: 5mL;
作为优选,HNO3的浓度为2%(w/v);Preferably, the concentration of HNO 3 is 2% (w/v);
作为优选,离心的转速为4000-5000r/min;Preferably, the centrifugal speed is 4000-5000r/min;
步骤(2)、目标分析物样品富集:Step (2), target analyte sample enrichment:
2-1、活化毛细管柱2-1. Activated capillary column
采用1%(w/v,g/mL)海美溴铵(HDMB)涂层熔融石英毛细管20-25分钟,以满足阴离子和毛细管之间相同EOF方向的条件。A 1% (w/v, g/mL) hexamethylene bromide (HDMB)-coated fused silica capillary was used for 20-25 min to satisfy the condition of the same EOF orientation between the anion and the capillary.
2-2、对活化毛细管柱进样前进行硼砂缓冲液冲洗5-10分钟。2-2. Rinse the activated capillary column with borax buffer for 5-10 minutes before injection.
作为优选,所述硼砂缓冲液浓度为25-100mM,优选为100mM。Preferably, the concentration of the borax buffer is 25-100 mM, preferably 100 mM.
作为优选,所述硼砂缓冲液pH为8.8-9.4,更为优选为9.2。Preferably, the pH of the borax buffer is 8.8-9.4, more preferably 9.2.
2-3、毛细管柱中,胶束和目标分析物混合后作为样品溶液在负压下注入堆叠30-240s,然后负压下注射作为有机溶剂的甲醇水溶液,被扫描的分析物由胶束带到MSS边界,以实现样品堆积、分离;其中所述胶束采用3-(N,N-二甲基棕榈氨基)丙烷磺酸盐PAPS。2-3. In the capillary column, the micelles and the target analyte are mixed and injected into the stack as a sample solution under negative pressure for 30-240s, and then an aqueous methanol solution as an organic solvent is injected under negative pressure. The scanned analyte is bound by the micelles. to the MSS boundary to achieve sample stacking and separation; wherein the micelles use 3-(N,N-dimethylpalmitamido)propane sulfonate PAPS.
作为优选,毛细管电泳条件:检测波长为192nm,分离负压为-20kV,温度为20℃。Preferably, the capillary electrophoresis conditions: the detection wavelength is 192nm, the separation negative pressure is -20kV, and the temperature is 20°C.
作为优选,所述胶束浓度为10-40mM,更为优选为20mM。Preferably, the micelle concentration is 10-40 mM, more preferably 20 mM.
作为优选,所述胶束的注入时间为180s。Preferably, the injection time of the micelle is 180s.
作为优选,所述胶束的注入负压为-10kV。Preferably, the injection negative pressure of the micelle is -10kV.
作为优选,所述甲醇水溶液的进样参数为注射动力-10kV、注射压力50mbar、注射时间5s。Preferably, the injection parameters of the methanol aqueous solution are injection power-10kV, injection pressure 50mbar, and injection time 5s.
作为优选,所述甲醇水溶液体积含量为40-100%(v/v),优选为60%(v/v)。Preferably, the volume content of the methanol aqueous solution is 40-100% (v/v), preferably 60% (v/v).
以下结合若干较佳实施例对本发明的技术方案作进一步的解释说明,但其中的实验条件和设定参数不应视为对本发明基本技术方案的局限。并且本发明的保护范围不限于下述的实施例。The technical solution of the present invention will be further explained below with reference to some preferred embodiments, but the experimental conditions and setting parameters therein should not be regarded as limitations to the basic technical solution of the present invention. And the protection scope of the present invention is not limited to the following embodiments.
CE条件为:CE conditions are:
检测波长:192nm。柱温:20℃。Detection wavelength: 192nm. Column temperature: 20°C.
毛细管柱:内径50μm,外径375μm,长度60cm,有效长度51.5cm。在第一次使用之前,新的毛细管柱要用1.0M NaOH溶液冲洗20分钟,0.1M NaOH溶液冲洗15min,纯水冲洗10min,1%HDMB涂层30min,运行缓冲液冲洗10min。为了实现良好的重复性,两针间用0.1M NaOH溶液冲洗2分钟,纯水冲洗2分钟,运行缓冲液冲洗5分钟。Capillary column:
分离电压:-20kV。Separation voltage: -20kV.
数据记录:HP化学工作站(Agilent)。Data logging: HP ChemStation (Agilent).
实施例1.考察胶束种类对检测效果的影响
将海带洗净干燥,粉碎之后通过100目筛,然后各准确称取200mg样品并置于15mL离心管中,加入5mL的2%HNO3,超声1h(40℃),然后室温下振摇2h,最后以4000r/min高速离心15min。提取物在分析之前用NaOH调至中和。The kelp was washed and dried, crushed and passed through a 100-mesh sieve, then 200 mg of each sample was accurately weighed and placed in a 15 mL centrifuge tube, 5 mL of 2% HNO 3 was added, sonicated for 1 h (40°C), and then shaken at room temperature for 2 h, Finally, centrifuge at 4000 r/min for 15 min. Extracts were neutralized with NaOH prior to analysis.
采用1%海美溴铵(HDMB)涂层熔融石英毛细管20分钟,以满足阴离子和毛细管之间相同EOF方向的条件。对活化毛细管柱进样前进行pH为9.2、100mM硼砂缓冲液冲洗5分钟。毛细管柱中,10mM胶束和10mg/L目标分析物混合后作为样品溶液在-10kV下注入堆叠60s,然后-10kV下50mbar注射100%MeOH5s,被扫描的分析物由胶束带到MSS边界,以实现样品堆积、分离;其中所述胶束采用3-(N,N-二甲基棕榈氨基)丙烷磺酸盐PAPS。毛细管电泳条件:检测波长为192nm,分离负压为-20kV,温度为20℃。Fused silica capillaries were coated with 1% hemexonium bromide (HDMB) for 20 min to satisfy the condition of the same EOF orientation between anions and capillaries. The activated capillary column was rinsed with 100 mM borax buffer pH 9.2 for 5 minutes before injection. In the capillary column, 10mM micelles and 10mg/L target analyte were mixed and injected into the stack as a sample solution at -10kV for 60s, and then 100% MeOH5s was injected at -10kV at 50mbar, the scanned analytes were brought from the micelles to the MSS boundary, In order to achieve sample stacking and separation; wherein the micelle adopts 3-(N,N-dimethylpalmitamido)propane sulfonate PAPS. Capillary electrophoresis conditions: the detection wavelength is 192 nm, the separation negative pressure is -20 kV, and the temperature is 20 °C.
阳离子表面活性剂是形成MSS过程的关键因素,它显著地影响了富集和分离效率。本实施例采用三种表面活性剂溶液PAPS、CTAB或CTAC作为胶束,以评价胶束对四种目标分析物堆积效率的影响。Cationic surfactant is a key factor in the formation of MSS, which significantly affects the enrichment and separation efficiency. In this example, three surfactant solutions, PAPS, CTAB or CTAC, were used as micelles to evaluate the effect of micelles on the stacking efficiency of the four target analytes.
如图2所示,与使用CTAC(c)相比,CTAB(b)使用可以获得更长的迁移时间和更高的灵敏度,CTAC的基线比CTAB更不均匀。同时,当CTAB和CTAC作为胶束时,As(V)峰不明显。显然,当应用PAPS(a)时,四种分析物的检测灵敏度最高,令人满意的分辨率最高。这可能是由于PAPS是一种含有季铵盐阳离子和磺酸阴离子的季铵盐两性表面活性剂。由于CMC(0.79×10-4M)最低,两性离子表面活性剂可以逆转EOF,减少分析物和涂层壁的吸附。它具有良好的表面性能,并与被分析物具有明显的协同效应。因此,选择了PAPS作为后续工作的胶束。As shown in Fig. 2, longer migration time and higher sensitivity can be obtained with CTAB (b) than with CTAC (c), which has a more heterogeneous baseline than CTAB. Meanwhile, when CTAB and CTAC act as micelles, the As(V) peak is not obvious. Clearly, when PAPS(a) is applied, the four analytes have the highest detection sensitivity and the highest satisfactory resolution. This may be due to the fact that PAPS is a quaternary ammonium amphoteric surfactant containing quaternary ammonium salt cations and sulfonic acid anions. With the lowest CMC (0.79×10-4M), zwitterionic surfactants can reverse the EOF and reduce the adsorption of analytes and the coated walls. It has good surface properties and a clear synergistic effect with the analyte. Therefore, PAPS was selected as the micelle for the follow-up work.
实施例2.考察PAPS浓度对检测效果的影响
在实施例1的基础上,选择PAPS作为胶束,并将PAPS浓度更改为0、5、10、20、30、40mM,其他条件不变。On the basis of Example 1, PAPS was selected as the micelle, and the PAPS concentration was changed to 0, 5, 10, 20, 30, and 40 mM, and other conditions remained unchanged.
胶束的浓度是影响胶束到溶剂堆积边界(MSSB)形成的关键参数。因此,对样品溶液中不同PAPS浓度进行分析,结果如图3所示。当表面活性剂浓度为0-20mM变化时,As(V)、MMA和DMA的峰面积逐渐增加,而胶束浓度为5-10mM时,As(Ⅲ)的峰面积急剧减少。而PAPS浓度从20mM进一步增加到40mM,四种分析物的峰高均略有降低。证明PAPS浓度的增加对MSS过程中胶束的形成有负面影响,因为低浓度的有机溶剂不符合逆转高κ分析物的μ*ep(a’)的条件。如果其浓度过高,则两性离子表面活性剂与分析物之间的亲和力过强,无法逆转MSSB处的μep(a’),从而导致MSS的失败。结果,在样品基质中选择了20mM的PAPS。The concentration of micelles is a key parameter affecting the formation of micelles to the solvent packing boundary (MSSB). Therefore, different PAPS concentrations in the sample solution were analyzed, and the results are shown in Figure 3. When the surfactant concentration was varied from 0 to 20 mM, the peak areas of As(V), MMA and DMA gradually increased, while the peak area of As(III) decreased sharply when the micelle concentration was varied from 5 to 10 mM. While the PAPS concentration was further increased from 20 mM to 40 mM, the peak heights for all four analytes decreased slightly. It was demonstrated that an increase in PAPS concentration negatively affects the formation of micelles during MSS, as low concentrations of organic solvents are not eligible to reverse μ*ep(a') for high-κ analytes. If its concentration is too high, the affinity between the zwitterionic surfactant and the analyte is too strong to reverse the μep(a') at MSSB, resulting in failure of MSS. As a result, 20 mM PAPS was selected in the sample matrix.
实施例3.考察甲醇含量对检测效果的影响
在实施例1的基础上,选择PAPS作为胶束,并将MeOH的浓度更改为40、60、80、100%(v/v),其他条件不变。On the basis of Example 1, PAPS was selected as the micelle, and the concentration of MeOH was changed to 40, 60, 80, 100% (v/v), and other conditions remained unchanged.
甲醇通常是MSS中的一种有机溶剂,它影响分析物和胶束之间的相互作用,逆转有效的电泳迁移率以实现富集。本实施例将MeOH单独注入两步叠加,将MeOH的百分比优化在40-100%(v/v)范围内,以获得其他条件下分析物的最佳分辨率和富集。Methanol is usually an organic solvent in MSS, which affects the interaction between analyte and micelles, reversing the effective electrophoretic mobility for enrichment. This example superimposes two steps of MeOH injection alone, and optimizes the percentage of MeOH in the range of 40-100% (v/v) to obtain the best resolution and enrichment of analytes under other conditions.
所得结果如图4所示。除As(Ⅲ)外,当甲醇浓度为40%(v/v)时,其他三种化合物的峰面积均小于使用60%时的峰面积。但当MeOH含量为60%~100%(v/v)时,三种化合物[As(V)、MMA、DMA]的峰值强度降低,随着MeOH百分比的增加,分析物的迁移时间延长。其原因可以证明被分析物对胶束的亲和力较弱,导致了较低的κ值,这是在有机溶剂的存在下发生的。随着甲醇百分比的增加,由于分析物对胶束的亲和力降低,κ值降低,从而扩大了扫描区的长度。然而,当应用80%(v/v)MeOH时,As(III)的检测灵敏度最高。因此,选择60%(v/v)MeOH进行进一步研究。The results obtained are shown in Figure 4. Except As(III), when the methanol concentration was 40% (v/v), the peak areas of the other three compounds were all smaller than those when 60% was used. However, when the MeOH content was 60%-100% (v/v), the peak intensities of the three compounds [As(V), MMA, DMA] decreased, and the migration time of the analytes was prolonged with the increase of MeOH percentage. The reason for this can be proven that the analyte has a weaker affinity for micelles, resulting in a lower κ value, which occurs in the presence of organic solvents. As the percentage of methanol increases, the κ value decreases due to the reduced affinity of the analyte for the micelles, thereby expanding the length of the scan region. However, the detection sensitivity of As(III) was highest when 80% (v/v) MeOH was applied. Therefore, 60% (v/v) MeOH was selected for further study.
实施例4.考察硼砂浓度对检测效果的影响
在实施例1的基础上,选择PAPS作为胶束,并将硼砂缓冲液的浓度更改为25、50、75、100mM,其他条件不变。On the basis of Example 1, PAPS was selected as the micelle, and the concentration of borax buffer was changed to 25, 50, 75, and 100 mM, and other conditions remained unchanged.
在BGS中使用硼砂缓冲液作为电解液,本实施例探究BGS中电解质的浓度对迁移时间和峰值强度均有显著影响。Borax buffer was used as electrolyte in BGS, and this example explores that the concentration of electrolyte in BGS has a significant effect on migration time and peak intensity.
图5A的电泳图显示,从25到100mM,表观迁移率(μapp)降低,与迁移时间成反比,结果如图5B所示。值得注意的是,溶液电流的增加是由于浓度的增加而引起的。证明EOF受硼砂缓冲液浓度的影响,缓冲液浓度随着BGS中硼砂缓冲液浓度的增加而降低。此外,增加的电流产生了更多的焦耳热量,这将导致基线噪声的增加(16-65μA)。综合考虑,本发明优选100mM的硼砂缓冲液。The electropherogram of Figure 5A shows that the apparent mobility ([mu]app) decreases from 25 to 100 mM, inversely proportional to the migration time, and the results are shown in Figure 5B. Notably, the increase in solution current is due to the increase in concentration. It was demonstrated that EOF was affected by borax buffer concentration, which decreased with increasing borax buffer concentration in BGS. Additionally, the increased current generates more Joule heat, which will result in an increase in baseline noise (16-65 μA). Comprehensive consideration, the present invention prefers 100mM borax buffer.
实施例5.考察缓冲液pH对检测效果的影响
在实施例1的基础上,选择PAPS作为胶束,并将硼砂缓冲液的pH更改为8.8、9.0、9.2、9.4,其他条件不变。On the basis of Example 1, PAPS was selected as the micelle, and the pH of the borax buffer was changed to 8.8, 9.0, 9.2, and 9.4, and other conditions remained unchanged.
砷化合物在CE中的迁移也受到其pKa值的影响,因此有必要研究BGS pH对砷种类分析的影响。本发明中砷种类为多基因酸,其表观电荷与它们自身的pKa以及BGS的pH有关。BGS pH为8.8-9.4,因为实验前研究表明,两步叠加在碱性pH下分析BGS更有效。此外,碱性条件确保了所有的As都以阴离子的形式迁移到阳极。The migration of arsenic compounds in CE is also affected by their pKa values, so it is necessary to study the effect of BGS pH on the analysis of arsenic species. Arsenic species in the present invention are polygenic acids whose apparent charge is related to their own pKa and pH of BGS. The BGS pH was 8.8-9.4 because pre-experimental studies showed that a two-step overlay was more efficient for BGS analysis at alkaline pH. Furthermore, alkaline conditions ensure that all As migrates to the anode in the form of anions.
结果表明,当pH值为9.0时,表观迁移率达到了最大值(图6)。当pH从9.0上升到9.4时,表观迁移率开始下降,迁移时间延长。在共电渗流模式下,由于熔融二氧化硅的表面被HDMB修饰,因此As物种的迁移方向与EOF相同。因此,被分析物的分离速度更快。同时,当BGS的pH为9.2时,四种分析物之间的分离度良好,在pH为9.2时得到最大峰值。为了获得更高的灵敏度,当表观迁移率低于9.0时,最好选择pH为9.2作为BGS。The results showed that the apparent mobility reached a maximum at pH 9.0 (Figure 6). When the pH increased from 9.0 to 9.4, the apparent mobility started to decrease and the migration time prolonged. In the co-electroosmotic flow mode, the As species migrates in the same direction as the EOF because the surface of the fused silica is decorated with HDMB. Therefore, the separation of the analytes is faster. Meanwhile, when the pH of BGS was 9.2, the resolution between the four analytes was good, and the maximum peak was obtained at pH 9.2. For higher sensitivity, when the apparent mobility is lower than 9.0, it is better to choose pH 9.2 as BGS.
实施例6.考察样品注射时间对检测效果的影响
在实施例1的基础上,选择PAPS作为胶束,并将样品溶液的注入时间更改为30、60、120、180、240s,其他条件不变。On the basis of Example 1, PAPS was selected as the micelle, and the injection time of the sample solution was changed to 30, 60, 120, 180, and 240 s, and other conditions remained unchanged.
注入时间通过直接改变注入体积,影响了分析物在MSS中的检测灵敏度、令人满意的分离效率和高堆积性能。60%甲醇的注入时间保持在5s(50mbar),样品溶液的注入时间变化为30-240s。The injection time affects the detection sensitivity, satisfactory separation efficiency, and high stacking performance of analytes in MSS by directly changing the injection volume. The injection time of 60% methanol was kept at 5 s (50 mbar), and the injection time of the sample solution was varied from 30 to 240 s.
从图7可以看出,从直方图中可以看出,当注射时间为30-180s时,通过扩大注射体积,增加了目标分析物的峰面积,获得了令人满意的堆积效率。然而,随着注入时间的逐渐增加,峰形变宽,基线紊乱,分析时间相对较长。在240s注射时,与180s相比,峰面积没有进一步扩大,四个分析物峰的最小分辨率(1.17)出现,导致分析物的灾难性分离。基于上述结果,优选180s为最佳注入时间,以获得令人满意的堆积效率和良好的分辨率。As can be seen from Figure 7, it can be seen from the histogram that when the injection time is 30-180 s, by enlarging the injection volume, the peak area of the target analyte is increased, and a satisfactory stacking efficiency is obtained. However, as the injection time gradually increased, the peak shape broadened, the baseline was turbulent, and the analysis time was relatively long. At the 240s injection, with no further expansion of the peak area compared to the 180s, a minimum resolution of four analyte peaks (1.17) occurred, leading to catastrophic separation of the analytes. Based on the above results, 180 s is preferred as the optimal implantation time to obtain satisfactory stacking efficiency and good resolution.
重复性考察Repeated study
在上述最佳实验条件下,计算了四种砷物种的毛细血管内和毛细血管间重现性的线性、检测限(LODs)和定量(LOQs)(n=3)。有关业绩的分析数字总结见表1。制备含砷0.05、0.10、0.25、0.50、1.00mg/L和20mM PAPS5种浓度水平的标准样品溶液,得到校准曲线。用As(V)、MMA、DMA和As(Ⅲ)的峰面积计算的决定系数(R2)分别为0.9992、0.9990、0.9990和0.9928。迁移时间和峰值面积的重现性RSD%均低于2.7%。浓度为1mg/L标准溶液,用以计算毛细血管内重现性RSD%。As(V)、MMA、DMA和As(Ⅲ)的毛细血管内迁移时间RSD%分别为1.0、0.8、0.7和0.5。目标分析物的峰值面积的毛细血管内RSD%范围为0.3~0.7。应用标准溶液(10mg/L)获得毛细管间重现性RSD%。As(V)、MMA、DMA和As(Ⅲ)迁移时间的毛细管间RSD百分比分别为1.1、1.6、2.3和2.7。四种砷物种的峰面积的毛细管间RSD%范围为0.5~0.9%。迁移时间和峰面积的重现性RSD%均令人满意。As(V)、MMA、DMA和As(Ⅲ)的峰面积LODs(S/N=3)分别为0.382、0.633、0.911和0.659ng/mL。LOQ在1.27~3.04ng/mL范围内,计算为信噪比为10。As(V)、As(Ⅲ)、MMA和DMA的富集因子分别为1230、840、3820和1450。Under the optimal experimental conditions described above, linearity, limits of detection (LODs) and quantifications (LOQs) were calculated for the intracapillary and intercapillary reproducibility of the four arsenic species (n=3). A summary of the analytical figures on performance is presented in Table 1. Standard sample solutions containing 0.05, 0.10, 0.25, 0.50, 1.00 mg/L and 20 mM PAPS were prepared to obtain a calibration curve. The coefficients of determination (R2 ) calculated from the peak areas of As(V), MMA, DMA and As(III) were 0.9992, 0.9990, 0.9990 and 0.9928, respectively. The reproducible RSD % of migration time and peak area were both below 2.7%. The concentration of the standard solution was 1 mg/L, and it was used to calculate the reproducible RSD% in capillaries. The intracapillary migration time RSD% of As(V), MMA, DMA and As(III) were 1.0, 0.8, 0.7 and 0.5, respectively. The % intracapillary RSD for the peak area of target analytes ranged from 0.3 to 0.7. A standard solution (10 mg/L) was used to obtain % RSD reproducibility between capillaries. The intercapillary RSD percentages for the migration times of As(V), MMA, DMA and As(III) were 1.1, 1.6, 2.3 and 2.7, respectively. The inter-capillary RSD% of the peak areas of the four arsenic species ranged from 0.5 to 0.9%. The reproducible RSD % of both migration time and peak area were satisfactory. The peak area LODs (S/N=3) of As(V), MMA, DMA and As(III) were 0.382, 0.633, 0.911 and 0.659 ng/mL, respectively. The LOQ ranged from 1.27 to 3.04 ng/mL, calculated as a signal-to-noise ratio of 10. The enrichment factors of As(V), As(III), MMA and DMA were 1230, 840, 3820 and 1450, respectively.
表1.线性回归数据、LOD和LOQTable 1. Linear regression data, LOD and LOQ
回收率实验Recovery experiment
通过分析1mg/L作为标准溶液的添加海带,评价了所开发技术的实用性。根据样品检测结果,海带样品中未检测到As(Ⅲ)和As(V)但含有痕量的MMA和DMA。加标样品的分析结果见表2。海带的回收率为89.3-120.6%。三次平行实验的目的是为了获得本方法的重现性。迁移时间和峰值面积的RSD%分别从5.3变化到6.2和0.9-4.1。The practicability of the developed technique was evaluated by analyzing the addition of kelp at 1 mg/L as a standard solution. According to the sample detection results, As(III) and As(V) were not detected in the kelp samples but contained trace amounts of MMA and DMA. The analytical results of the spiked samples are shown in Table 2. The recovery rate of kelp was 89.3-120.6%. The purpose of three parallel experiments is to obtain the reproducibility of this method. The RSD% of migration time and peak area varied from 5.3 to 6.2 and 0.9–4.1, respectively.
表2.加标样品的分析结果Table 2. Analysis results of spiked samples
Claims (10)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202210481619.3A CN114778264A (en) | 2022-05-05 | 2022-05-05 | Method for simultaneously accumulating, enriching and separating multiple arsenic forms in natural medicine on line based on micelle-solvent accumulation |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202210481619.3A CN114778264A (en) | 2022-05-05 | 2022-05-05 | Method for simultaneously accumulating, enriching and separating multiple arsenic forms in natural medicine on line based on micelle-solvent accumulation |
Publications (1)
Publication Number | Publication Date |
---|---|
CN114778264A true CN114778264A (en) | 2022-07-22 |
Family
ID=82435674
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202210481619.3A Pending CN114778264A (en) | 2022-05-05 | 2022-05-05 | Method for simultaneously accumulating, enriching and separating multiple arsenic forms in natural medicine on line based on micelle-solvent accumulation |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN114778264A (en) |
-
2022
- 2022-05-05 CN CN202210481619.3A patent/CN114778264A/en active Pending
Non-Patent Citations (1)
Title |
---|
YALING YU等: "Two-step micelle-to-solvent stacking of arsenic species from foods in permanently coated tubing for capillary electrophoresis", 《JOURNAL OF CHROMATOGRAPHY A》, 3 May 2022 (2022-05-03), pages 1 - 9 * |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Quirino | Micelle to solvent stacking of organic cations in capillary zone electrophoresis with electrospray ionization mass spectrometry | |
Bjørnsdottir et al. | Chiral separation in non-aqueous media by capillary electrophoresis using the ion-pair principle | |
Tjørnelund et al. | Use of metal complexation in non-aqueous capillary electrophoresis systems for the separation and improved detection of tetracyclines | |
Rezazadeh et al. | Electromembrane surrounded solid phase microextraction: A novel approach for efficient extraction from complicated matrices | |
Cheng et al. | Sensitive arsenic analysis by carrier-mediated counter-transport single drop microextraction coupled with capillary electrophoresis | |
Rezazadeh et al. | Application of a new nanocarbonaceous sorbent in electromembrane surrounded solid phase microextraction for analysis of amphetamine and methamphetamine in human urine and whole blood | |
Nunez et al. | Solid-phase extraction and sample stacking–capillary electrophoresis for the determination of quaternary ammonium herbicides in drinking water | |
Kim et al. | On-line sample preconcentration of cationic analytes by dynamic pH junction in capillary electrophoresis | |
Gottardo et al. | Micellar electrokinetic chromatography: A new simple tool for the analysis of synthetic cannabinoids in herbal blends and for the rapid estimation of their log P values | |
Muijselaar et al. | On-line coupling of partial-filling micellar electrokinetic chromatography with mass spectrometry | |
Kalyankar et al. | Applications of micellar liquid chromatography in bioanalysis: a review | |
Arias et al. | Determination of the β-blocker atenolol in plasma by capillary zone electrophoresis | |
Caslavska et al. | Rapid analysis of furosemide in human urine by capillary electrophoresis with laser-induced fluorescence and electrospray ionization-ion trap mass spectrometric detection | |
Guo et al. | Ionic polymer enhanced electrophoresis in plastic microchips for rapid and robust determination of rhodamine dyes | |
Yao et al. | The cation-selective exhaustive injection and sweeping capillary electrophoresis method for the analysis of chlorpheniramine enantiomers in rat plasma | |
Carrero et al. | Analysis of haloacetic acid mixtures by HPLC using an electrochemical detector coated with a surfactant-nafion film | |
Yu et al. | Two-step micelle-to-solvent stacking of arsenic species from foods in permanently coated tubing for capillary electrophoresis | |
Yeh et al. | Human serum albumin-coated gold nanoparticles for selective extraction of lysozyme from real-world samples prior to capillary electrophoresis | |
Dos Santos et al. | Amphetamine and derivatives in natural weight loss pills and dietary supplements by capillary electrophoresis-tandem mass spectrometry | |
Wang et al. | Method development for the determination of coumarin compounds by capillary electrophoresis with indirect laser-induced fluorescence detection | |
Aguilar et al. | Analysis of histones by on-line capillary zone electrophoresis–electrospray ionisation mass spectrometry | |
Motomizu et al. | Separation and determination of divalent metal ions with UV-absorbing chelating agents by capillary electrophoresis | |
Bagheri et al. | A novel strategy based on surfactant assisted electromembrane extraction for the determination of dicamba and 2, 4-DB as model herbicides in real water samples | |
Ribeiro et al. | Fast determination of diphenhydramine, pyridoxine, and 8-chlorotheophylline by capillary electrophoresis with capacitively coupled contactless conductivity detection | |
CN114778264A (en) | Method for simultaneously accumulating, enriching and separating multiple arsenic forms in natural medicine on line based on micelle-solvent accumulation |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination |